Importantly, these observations suggest that anti-hormone therapy regimens, by increasing the BC cell expression of PDL1, may potentially enhance the efficacy of immunotherapies targeting the PD1/PDL1 axis (Figure 4), but combination approaches associating hormone therapies and anti-PD1/PDL1-based immunotherapies remain to be formally evaluated. This evidence concerns the gene CD274 and breast cancer.